Efficacy of Metformin in Preventing Diabetes in China

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1724 participants.

Also called NCT03441750

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 1,724 participants (enrolled count) (from the registry)
Sponsor
Chinese Association of Geriatric Research (from the registry)
Registry
  • NCT NCT03441750
Other papers using this trial's data
  • Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial The lancet. Diabetes & endocrinology, 2023-08 DOI, PubMed 37414069 PubMed links an erratum for this paper. Erratum: PMID 37804853

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03441750. Randomized; no masking; primary purpose prevention. Start 2017-04-25 (actual); primary completion 2021-06-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of Metformin in Preventing Diabetes in China
Acronym
ChinaDPP
Condition
PreDiabetes
Intervention (Drug)
metformin
Intervention (Other)
Standard lifestyle intervention
Lead sponsor
Chinese Association of Geriatric Research (class: other)

Record details

Record id
cardio:ct-nct03441750
Content hash
735594025495590758577622fc4cef99fa7c7970517d9dc944a57f8db62e66c1